This proposal responds to NIH RFA-AI-05-002. It describes the University of Washington Clinical HIV Integrated Research Program (UW CHIRP). The purpose of the UW CHIRP is to perform exemplary, cost effective HIV prevention and therapeutic research in adults, adolescents, and children. The UW CHIRP has been formed by integration of four existing, NIH-funded, network-affiliated HIV clinical research sites (CRSs). These CRSs are the UW HIV Prevention Trials Unit (HPTU) CRS, UW AIDS Clinical Trials Unit (ACTU) CRS, UW Primary Infection Clinic (PIC) CRS, and the UW International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) CRS. An administrative unit called the UW Clinical Trials Unit (CTU) will oversee the CRSs. The four CRSs will collaborate with the HIV Prevention Trials Network (HPTN), AIDS Clinical Trials Group (ACTG), ACTG, and the IMPAACT Group, respectively. UW CHIRP has five specific aims: 1) Organize, integrate, and coordinate the infrastructure, personnel, and facilities of UW and our CRSs to maximize efficiency and cost-effectiveness in conducting Network clinical trials;2) Ensure that all elements of the UW CHIRP meet necessary regulatory requirements, and perform to the standards of each affiliated Network;3) Foster new investigators and clinical research staff, especially women and minorities, and provide our clinical trials expertise to our Mentoring Partners;4) Contribute scientific expertise to the HPTN, ACTG, and IMPAACT Networks to develop and implement relevant scientific agendas, and to design protocols to support these Networks'scientific agendas and research plans;and 5) Organize, integrate, and coordinate our outreach efforts and connections to the community, including continuing our Prevention and Treatment Community Advisory Boards (CABs), to maximize access and enrollment of a broad diversity of subjects into Network protocols, including women, racial/ethnic minorities, and youth. The proposal describes the organization and management plan for each part of UW CHIRP;the scientific expertise, scientific contributions, and mentoring experience of its highly experienced investigators;and the plans for community interactions that will focus on reaching women, minorities and youth. It describes three proposed international Mentoring Partnerships that are extensions of ongoing collaborations. The UW CHIRP brings together a highly productive, experienced team of domestic investigators, each of whom has made a significant contribution to HIV prevention and/or therapeutic research. With the new structure, UW CHIRP will increase collaborations and efficiencies, and will continue to make major contributions to HIV prevention and therapeutic research in order to impact the worldwide HIV/AIDS epidemic. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069434-07
Application #
8401177
Study Section
Special Emphasis Panel (ZAI1-MPM-A (M2))
Program Officer
Potter, Dara G
Project Start
2006-12-01
Project End
2014-05-30
Budget Start
2012-12-01
Budget End
2014-05-30
Support Year
7
Fiscal Year
2013
Total Cost
$1,031,902
Indirect Cost
$422,569
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
De Boni, Raquel B; Zheng, Lu; Rosenkranz, Susan L et al. (2016) Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. Drug Alcohol Depend 159:174-80
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Ma, Qing; Vaida, Florin; Wong, Jenna et al. (2016) Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol 22:170-8
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Gupta, S K; Kitch, D; Tierney, C et al. (2015) Markers of renal disease and function are associated with systemic inflammation in HIV infection. HIV Med 16:591-8
Longenecker, Chris T; Kitch, Douglas; Sax, Paul E et al. (2015) Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s. J Acquir Immune Defic Syndr 69:168-77
Gross, Robert; Zheng, Lu; La Rosa, Alberto et al. (2015) Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial. Lancet HIV 2:e12-9
Gross, Robert; Zheng, Lu; La Rosa, Alberto et al. (2015) Partner-Focused Adherence Intervention for Second-line Antiretroviral Therapy: A Multinational Randomized Trial (ACTG A5234). Lancet HIV 2:e12-e19
Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9

Showing the most recent 10 out of 91 publications